Tuesday, November 17, 2026

Neuroimmune transcriptional signatures across repeat expansion ataxias in the human brain

Chen, Z., Hicks, A.R., Brenton, J. et al. Neuroimmune transcriptional signatures across repeat expansion ataxias in the human brain. Acta Neuropathol 152, 70 (2026). doi:10.1007/s00401-026-03115-1 

 We identify immune and inflammatory activation as a recurring molecular feature of disease and highlight the contribution of non-neuronal cell populations to the ataxia disease state. These findings extend current understanding of repeat expansion disorders and suggest that immune-related pathways may represent shared components of disease biology across genetically distinct ataxias and potential targets for therapeutic intervention. Continued investigation of these processes in human tissue and experimental models will be important for clarifying their role in disease initiation and progression and for determining whether modulation of immune responses may represent a viable therapeutic strategy in hereditary ataxia.

Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone

Figueroa, F.; Salinas, L.; Montgomery-Bowie, C.B.; Sellers, R.; Sims, L.; Cox, G.P.; Golove, S.L.; Thai, P.N.; Chiamvimonvat, N.; Cortopassi, G.; et al. Targeting Nrf2 Signaling in Friedreich’s Ataxia Cardiomyopathy: Sex-Dependent Therapeutic Responses to Dimethyl Fumarate and Omaveloxolone. Antioxidants 2026, 15, 1490. doi:10.3390/antiox15111490 

 DMF partially improved cardiac function in males, increasing stroke volume, enhancing metabolic flexibility, and restoring mitochondrial enzyme activity; however, diastolic dysfunction persisted. OMAV treatment was associated with female-specific electrophysiological abnormalities, including increased arrhythmic burden and reduced J-wave amplitude, with persistent fibrotic remodeling. Both treatments attenuated region-specific cardiomyocyte atrophy in FXNKD males and females. These findings suggest that Nrf2 activation alone is insufficient to reverse FA-associated cardiomyopathy and reveal sex-dependent therapeutic responses. Further investigation of complementary treatment strategies may help address persistent cardiac dysfunction and remodeling in FA.